IN2014MN00933A - - Google Patents
Info
- Publication number
- IN2014MN00933A IN2014MN00933A IN933MUN2014A IN2014MN00933A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A IN 933MUN2014 A IN933MUN2014 A IN 933MUN2014A IN 2014MN00933 A IN2014MN00933 A IN 2014MN00933A
- Authority
- IN
- India
- Prior art keywords
- insulin analogue
- therapeutic agent
- present
- provides
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000004026 insulin derivative Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110422095 | 2011-12-15 | ||
| PCT/CN2012/085054 WO2013086927A1 (zh) | 2011-12-15 | 2012-11-22 | 人胰岛素类似物及其酰化衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00933A true IN2014MN00933A (enrdf_load_stackoverflow) | 2015-05-01 |
Family
ID=48611849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN933MUN2014 IN2014MN00933A (enrdf_load_stackoverflow) | 2011-12-15 | 2012-11-22 |
Country Status (14)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2908373T3 (es) | 2015-08-25 | 2022-04-28 | Novo Nordisk As | Nuevos derivados de insulina y los usos médicos de los mismos |
| CN106496322A (zh) * | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
| CN105491227A (zh) * | 2015-11-20 | 2016-04-13 | 努比亚技术有限公司 | 一种消息排列方法和终端 |
| EP3260548A1 (en) | 2016-06-21 | 2017-12-27 | Enzypep B.V. | Enzymatic coupling of (oligo)peptides to the b-chain of an insulin receptor ligand |
| WO2018024186A1 (zh) * | 2016-08-02 | 2018-02-08 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| BR112020015457A2 (pt) * | 2018-02-01 | 2020-12-08 | Jiangsu Hengrui Medicine Co., Ltd. | Composição farmacêutica compreendendo derivado acilado de análogo de insulina humana e método de preparação da mesma |
| EP3750998A4 (en) * | 2018-02-09 | 2022-02-23 | Jiangsu Hengrui Medicine Co., Ltd. | CODON-OPTIMIZED PRECURSOR GENE AND SIGNAL PEPTID GENE OF HUMAN INSULIN ANALOGUE |
| CA3122636A1 (en) | 2018-12-11 | 2020-06-18 | Sanofi | Insulin analogs having reduced insulin receptor binding affinity |
| CN111909255A (zh) * | 2019-05-10 | 2020-11-10 | 宁波鲲鹏生物科技有限公司 | 胰岛素衍生物及其制备方法 |
| PH12022551094A1 (en) | 2019-12-11 | 2024-06-24 | Novo Nordisk As | Novel insulin analogues and uses thereof |
| US20230126068A1 (en) | 2019-12-30 | 2023-04-27 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin Derivative |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| JP2024521757A (ja) * | 2021-05-24 | 2024-06-04 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 新規なアシル化インスリンアナログ |
| EP4361174A1 (en) | 2021-06-25 | 2024-05-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin-containing pharmaceutical composition |
| EP4471053A1 (en) | 2022-01-28 | 2024-12-04 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin |
| CN118063589A (zh) * | 2024-02-04 | 2024-05-24 | 乐普健糖药业(重庆)有限公司 | 一种超长效胰岛素类似物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| JPH03506023A (ja) | 1988-07-20 | 1991-12-26 | ノボ ノルデイスク アクツイエセルスカプ | ポリペプチド |
| AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
| IL110977A (en) * | 1993-09-17 | 2000-06-29 | Novo Nordisk As | Human insulin derivative and pharmaceutical composition comprising it |
| CN1195777A (zh) | 1997-05-28 | 1998-10-14 | 姚维明 | 电力拖动实验仪 |
| EP1246845B1 (en) * | 1999-12-29 | 2008-05-28 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogs |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7193035B2 (en) | 2002-10-29 | 2007-03-20 | Sanofi-Aventis Deutschland Gmbh | Crystals of insulin analogs and processes for their preparation |
| CN1780854A (zh) | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
| SI2107069T1 (sl) | 2003-08-05 | 2013-04-30 | Novo Nordisk A/S | Novi inzulinski derivati |
| MXPA06001283A (es) * | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
| CN101721712A (zh) * | 2008-10-21 | 2010-06-09 | 何明磊 | 一种双链聚乙二醇－胰岛素复合物及其制备方法 |
-
2012
- 2012-11-22 IN IN933MUN2014 patent/IN2014MN00933A/en unknown
- 2012-11-22 CN CN201280011736.8A patent/CN103443122B/zh active Active
- 2012-11-22 EP EP12857862.2A patent/EP2784085A4/en not_active Withdrawn
- 2012-11-22 MX MX2014006698A patent/MX2014006698A/es unknown
- 2012-11-22 WO PCT/CN2012/085054 patent/WO2013086927A1/zh active Application Filing
- 2012-11-22 AU AU2012350586A patent/AU2012350586B2/en not_active Ceased
- 2012-11-22 US US14/363,328 patent/US9458219B2/en not_active Expired - Fee Related
- 2012-11-22 CN CN201510174792.9A patent/CN104788556A/zh active Pending
- 2012-11-22 KR KR1020147018616A patent/KR20140104994A/ko not_active Withdrawn
- 2012-11-22 RU RU2014127270A patent/RU2014127270A/ru not_active Application Discontinuation
- 2012-11-22 BR BR112014013483A patent/BR112014013483A2/pt not_active IP Right Cessation
- 2012-11-22 CA CA2858253A patent/CA2858253A1/en not_active Abandoned
- 2012-11-22 JP JP2014546293A patent/JP6153206B2/ja not_active Expired - Fee Related
- 2012-11-30 TW TW101144976A patent/TW201323439A/zh unknown
-
2014
- 2014-06-17 ZA ZA2014/04417A patent/ZA201404417B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012350586A1 (en) | 2014-07-03 |
| TW201323439A (zh) | 2013-06-16 |
| EP2784085A1 (en) | 2014-10-01 |
| CN104788556A (zh) | 2015-07-22 |
| WO2013086927A1 (zh) | 2013-06-20 |
| HK1188795A1 (zh) | 2014-05-16 |
| CN103443122B (zh) | 2016-05-11 |
| MX2014006698A (es) | 2014-07-09 |
| CN103443122A (zh) | 2013-12-11 |
| US20140329745A1 (en) | 2014-11-06 |
| AU2012350586B2 (en) | 2017-02-02 |
| JP2015501819A (ja) | 2015-01-19 |
| KR20140104994A (ko) | 2014-08-29 |
| ZA201404417B (en) | 2016-07-27 |
| CA2858253A1 (en) | 2013-06-20 |
| US9458219B2 (en) | 2016-10-04 |
| BR112014013483A2 (pt) | 2019-09-24 |
| EP2784085A4 (en) | 2015-07-08 |
| JP6153206B2 (ja) | 2017-06-28 |
| RU2014127270A (ru) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00933A (enrdf_load_stackoverflow) | ||
| ZA201505849B (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| PL2547323T3 (pl) | Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| SG11201401921YA (en) | Formulations for the treatment of diabetes | |
| EA201390796A1 (ru) | Применение ацилированного аналога глюкагона | |
| AP3155A (en) | Methods of administering pirfenidone therapy | |
| EP2677964A4 (en) | Prosthetic heart valve delivery apparatus | |
| PL2683395T3 (pl) | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 | |
| MX349004B (es) | Nuevos compuestos. | |
| EP2782631A4 (en) | IMPLANTABLE APPARATUS FOR USE IN THE ADMINISTRATION OF A SOLID-LIQUID MEDICAMENT, ASSOCIATED FORMULATIONS AND METHODS OF USE | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| IL254446A0 (en) | Implantable drug delivery preparations and treatment methods thereof | |
| WO2012071369A3 (en) | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease | |
| WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
| SG178596A1 (en) | Methods of treatment using anti-oxidized ldl antibodies | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| IN2014DN03010A (enrdf_load_stackoverflow) | ||
| WO2012123519A3 (en) | Human insulin analogues and derivatives comprising cysteine substitutions | |
| EP2402342A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | |
| PL2609926T3 (pl) | Zapobieganie lub leczenie bolesnej polineuropatii poprzez podawanie glikokrzemianu | |
| HUP1100723A2 (en) | Use of estrogen derivatives for preparing medicament for the treatment of psychiatric diseases | |
| HK40098442A (en) | Prosthetic heart valve delivery apparatus | |
| WO2011026193A8 (en) | Cytotoxic compounds | |
| UA42333U (uk) | Спосіб лікування алергічних захворювань |